Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (13202)	9/29/2004 3:35:02 PM
From: Biomaven	Respond to of 52153

The Avanir drug raises an interesting question - where you have a drug that is a combination of two existing generic drugs, just how much can you charge for it? At some point doctors will tell patients to go buy some cough syrup and take it with some quinidine pills. But if doctors do this, are they opening themselves up to a charge of patent infringement? And of course the PK issues mean that doctors won't necessarily know what doses to use. Nitromed's BiDil faces the same issue. (And if it's the NMDA activity of dextromethorphan that's effective here, might FRX's memantine not work even better?) Peter